Neurogene Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $925,000 | $0 | — | — |
| Operating income | -$103.3M | -$82.6M | -$55.6M | -$56.5M | -$60.7M |
| Operating expenses | $103.3M | $83.5M | $55.6M | $56.5M | $60.7M |
| Cash from operations | -$77.2M | -$70.6M | -$51.4M | -$52.8M | -$47.6M |
| Capital expenditure | $1.2M | $808,000 | $321,000 | $2.2M | $3.3M |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M | -$55.1M | -$50.8M |
| Impairments | $120,000 | $91,000 | $0 | $0 | — |
| Total assets | $288.6M | $335.7M | $222.6M | $109.3M | $163.3M |
| Total liabilities | $23.7M | $25.4M | $36.5M | $10.6M | $20.4M |
Shares outstanding 15.8M · Free float 45.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.